Riduttasi

Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase.Cost-effective and quality-assured.

Turosteride is a small molecule steroidal 5α-reductase (5α-reductase) inhibitor.Turosteride has antitumor activity for the treatment of oncologic diseases and

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR.

Potent TR inhibitor with IC50: 3.3μM, also inhibits glutathione reductase (IC50: 64.8μM) and T. brucei (EC50: 1μM).

Alconil is a biochemical.

MK 0434 is a steroid 5α-reductase inhibitor and hormone antagonist associated with a significant reduction in DHT.

Imirestat (HOE 843) is an aldose reductase inhibitor that can be used in diabetes research.

Fluvastatin sodium (Fluvastatin sodium salt), a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), is a commonly used cholesterol

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM).

Trimethoprim (NSC-106568) inhibits dihydrofolate reductase, CYP2C8, and OCT2 - an antibacterial agent.

Epalrestat (ONO2235), an aldose reductase inhibitor, helps manage diabetic neuropathy symptoms and slows disease progression.

1264 small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.

ALR2-IN-1: potent, selective inhibitor of ALR2 (IC50=1.42 μM), antiglycemic, antioxidant; for diabetes research.

AKR1Cs-IN-1 (Compound 29) is an effective and broad-spectrum inhibitor of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). It achieves subtype inhibition by simultaneously binding to the SP2 and SP3 pockets, thereby blocking metabolic pathways related to drug resistance. In enzyme assays, AKR1Cs-IN-1 exhibits significant inhibitory activity with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM for AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. The compound shows excellent resensitizing effects in doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, effectively enhancing the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on breast cancer resistance.

ALR2-IN-6 (compound 9) is a potent competitive inhibitor of ALR2, with a Ki value of 0.064 μM. It is applicable in research related to neuropathy, retinopathy, and nephropathy.

Antitumor agent-195 (compound 16c) is a dual-targeting agent that simultaneously targets STAT3 and NQO1. At a concentration of 1 μM, it significantly inhibits the phosphorylation of STAT3 at the Tyr705 site and effectively induces apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells. As a substrate of NQO1, Antitumor agent-195 markedly increases ROS production, causing severe DNA damage in a dose-dependent manner. It also demonstrates strong antitumor properties in MDA-MB-231 xenograft models.

Isomer-Turosteride, a novel 5α-reductase inhibitor, reduces prostate DHT and has anticancer properties without raising T levels.

DDHF20 is an inhibitor of Staphylococcus aureus, specifically targeting and inhibiting its thioredoxin reductase (TrxR) by acting as a competitive inhibitor at the NADPH binding site. DDHF20 shows potential for research in combating infections related to Staphylococcus aureus.

SPR inhibitor 3 blocks sepiapterin reductase, eases neuropathic pain, and lowers BH4 with high affinity (IC50: 74 nM cell-free, 5.2 μM cell-based).